Form 4 for DGX Quest Diagnostics
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0001022079-25-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-14 | 2025-02-12 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $0.00 | +2,269 | 12.1K | +23% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $0.00 | +8,702 | 8,702 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | A | A | 2,269 | $0.00 | 12,066 | D | — | — | (F1) Represents an award of restricted stock units. (F2) The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 4. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-02-12 | A | A | 8,702 | $0.00 | 8,702 | D | $165.30 · 2035-02-12 to — | 8,702 Common Stock | (F4) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |